Free tool
FAERS Monitor: Nilotinib D-Tartrate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218922 or its brand name (Nilotinib D-Tartrate, Nilotinib D-Tartrate). Reports on generic versions are filed under their own applications.
Reports
4,067
Serious
3,797
93% of reports
Hospitalization
811
Death reported
635
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug intolerance430
- drug ineffective349
- drug resistance348
- diarrhoea338
- dyspnoea335
- fatigue325
- nausea306
- headache302
- myalgia281
- arthralgia272
- abdominal pain271
- pleural effusion270
- pyrexia260
- pruritus250
- asthenia248
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 17 |
| 2010 | 19 |
| 2011 | 43 |
| 2012 | 95 |
| 2013 | 88 |
| 2014 | 154 |
| 2015 | 157 |
| 2016 | 215 |
| 2017 | 177 |
| 2018 | 267 |
| 2019 | 440 |
| 2020 | 375 |
| 2021 | 347 |
| 2022 | 323 |
| 2023 | 306 |
| 2024 | 365 |
| 2025 | 341 |
| 2026 | 322 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,092 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug resistanceSignal | 348 | 71.0 | 64.2 | 23,655 |
| drug intoleranceSignal | 430 | 23.1 | 21.1 | 9,079 |
| pleural effusionSignal | 270 | 23.0 | 20.5 | 5,662 |
| myalgiaSignal | 281 | 8.6 | 7.6 | 1,881 |
| abdominal painSignal | 271 | 6.0 | 5.4 | 1,143 |
| pyrexiaSignal | 260 | 3.9 | 3.5 | 564 |
| astheniaSignal | 248 | 3.4 | 3.0 | 428 |
| arthralgiaSignal | 272 | 3.4 | 3.0 | 463 |
| pruritusSignal | 250 | 3.4 | 3.0 | 421 |
| dyspnoeaSignal | 335 | 3.1 | 2.8 | 476 |
| diarrhoeaSignal | 338 | 2.7 | 2.4 | 374 |
| headacheSignal | 302 | 2.5 | 2.2 | 276 |
| fatigueSignal | 325 | 2.2 | 1.9 | 209 |
| nausea | 306 | 2.0 | 1.8 | 158 |
| drug ineffective | 349 | 1.4 | 1.2 | 37 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.